Bms-599626

CAS No.	714971-09-2
MDL No.	MFCD10565678
MF	C₂₇H₂₇FN₈O₃
MW	530.60
InChI Key	LUJZZYWHBDHDQX-QFIPXVFZSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	714971-09-2
Product Name	Bms-599626

Biological Targets

EGFR·ERBB2·ERBB4

Associated Conditions

Paraganglioma·neoplasm·cancer

* The information provided here is compiled from public sources and is for reference only.

Bms-599626

CAS No.	714971-09-2
MDL No.	MFCD10565678
MF	C₂₇H₂₇FN₈O₃
MW	530.60
InChI Key	LUJZZYWHBDHDQX-QFIPXVFZSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	714971-09-2
Product Name	Bms-599626

Biological Targets

EGFR·ERBB2·ERBB4

Associated Conditions

Paraganglioma·neoplasm·cancer

* The information provided here is compiled from public sources and is for reference only.

Bms-599626

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Bms-599626

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Bms-599626

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Discovery of Daclatasvir as a potential PD-L1 inhibitor from drug repurposing.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases.

Bms-599626

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Discovery of Daclatasvir as a potential PD-L1 inhibitor from drug repurposing.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases.

Documentation